PHMMF Stock - Pharma Mar, S.A.
Unlock GoAI Insights for PHMMF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $174.85M | $158.15M | $196.34M | $229.83M | $269.96M |
| Gross Profit | $166.67M | $148.54M | $182.70M | $213.39M | $256.24M |
| Gross Margin | 95.3% | 93.9% | 93.1% | 92.8% | 94.9% |
| Operating Income | $6.47M | $-3,827,000 | $44.07M | $92.45M | $155.94M |
| Net Income | $26.13M | $1.14M | $49.36M | $92.86M | $137.26M |
| Net Margin | 14.9% | 0.7% | 25.1% | 40.4% | 50.8% |
| EPS | $1.49 | $0.06 | $2.73 | $5.14 | $7.50 |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Visit WebsiteEarnings History & Surprises
PHMMFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 22, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.18 | $-0.32 | -77.7% | ✗ MISS |
Q3 2025 | Jul 30, 2025 | $0.04 | $1.59 | +4399.2% | ✓ BEAT |
Q2 2025 | Apr 21, 2025 | $0.34 | $-0.25 | -173.4% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $1.00 | $1.10 | +10.0% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $0.23 | $0.24 | +6.4% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $0.01 | $0.08 | +604.0% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | $-0.08 | $0.14 | +286.8% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.09 | $-0.43 | -581.5% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | $0.23 | $0.09 | -61.6% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.04 | $0.30 | +598.8% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $0.22 | $0.08 | -60.9% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | $0.97 | $0.08 | -91.5% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | — | $0.71 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.75 | — | — |
Q1 2022 | Mar 31, 2022 | — | $1.35 | — | — |
Q4 2021 | Dec 31, 2021 | — | $2.40 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.74 | — | — |
Q2 2021 | Jun 30, 2021 | — | $1.25 | — | — |
Latest News
Frequently Asked Questions about PHMMF
What is PHMMF's current stock price?
What is the analyst price target for PHMMF?
What sector is Pharma Mar, S.A. in?
What is PHMMF's market cap?
Does PHMMF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PHMMF for comparison